Novel PDE5 inhibitors for the treatment of male erectile dysfunction

Reprod Biomed Online. 2003 Oct-Nov;7(4):456-61. doi: 10.1016/s1472-6483(10)61890-1.

Abstract

Erectile dysfunction (ED) affects the lives of approximately 150 million men worldwide. ED may be a cause of male sub-fertility in a significant proportion of patients. There is now an expanding armamentarium for the management of ED, including oral agents such as phosphodiesterase type 5 (PDE5) inhibitors. PDE5 inhibitors may also be useful in situations of temporary ED in couples undergoing IVF. Two novel PDE5 inhibitors have been commercially launched in the European Union in the first quarter of 2003. This article reviews the pharmacology and clinical efficacy of these new agents and their potential role in treating patients with male sub-fertility.

Publication types

  • Review

MeSH terms

  • 3',5'-Cyclic-GMP Phosphodiesterases / antagonists & inhibitors*
  • Carbolines / therapeutic use
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • Dose-Response Relationship, Drug
  • Erectile Dysfunction / drug therapy*
  • Humans
  • Imidazoles / therapeutic use
  • Infertility, Male / drug therapy*
  • Inhibitory Concentration 50
  • Male
  • Models, Biological
  • Models, Chemical
  • Nitric Oxide / metabolism
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Piperazines / therapeutic use
  • Purines
  • Sildenafil Citrate
  • Sulfones
  • Tadalafil
  • Triazines
  • Vardenafil Dihydrochloride

Substances

  • Carbolines
  • Imidazoles
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Triazines
  • Nitric Oxide
  • Vardenafil Dihydrochloride
  • Tadalafil
  • Sildenafil Citrate
  • 3',5'-Cyclic-GMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • PDE5A protein, human